Eisai Completes Rolling Submission to US FDA for LEQEMBI (R) IQLIK (TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback